The successful choice of hit compounds during drug development programs involves the
integration of structure-activity relationship (SAR) studies with pharmacokinetic …

This study focuses on the cytotoxic activity of ruthenium (II) complexes, denoted as Ru1–8,
which exhibit coordination with nitrogen (amine and amide), oxygen, and sulfur donor …

Background: Ruthenium-based anti-cancer compounds are proposed as viable alternatives
that might circumvent the disadvantages of platinum-based drugs, the only metallodrugs in …

This work reports on advances in the development of Werner-type ruthenium (II) and
ruthenium (III) complexes and organoruthenium (II) compounds as potential anticancer …

There is still high anticipation among oncology metallodrug developers that a real
breakthrough can be gained due to substituting platinum, as a principal component of all …

A set of structurally related Ru (η 5-C 5 H 5) complexes with bidentate N, N′-
heteroaromatic ligands have been evaluated as prospective metallodrugs, with focus on …

The ruthenium compound KP1019 has demonstrated promising anticancer activity in a pilot
clinical trial. This study aims to evaluate the intracellular uptake/binding patterns of KP1019 …

A series of organoruthenium (II) chlorido complexes with fluorinated O, O-ligands [(η6-p-
cymene) Ru (F3C-acac-Ar) Cl](1a–6a) and their respective 1, 3, 5-triaza-7 …

Ruthenium (II)-arene complexes are promising drug candidates for the therapy of solid
tumors. In previous work, seven new compounds of the general formula [Ru (η 6-p …

Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH+)[RuIIICl4
(Im)(S-dmso)], where Im= imidazole and S-dmso= S-bound dimethylsulfoxide) or KP1019 …